Teladoc Health (TDOC) shares are rising in Monday's trading session following the findings that the company's AI models have contributed to positive growth in diabetes management and patient engagement.
Yahoo Finance Health's Anjalee Khemlani details Teladoc's expansion into diabetes care through its 2020 acquisition of Livongo.
For more expert insights and the latest market trends, click here to watch this entire episode of Market Domination.
This post Luke Carberry Morgan.
Video Transcript
Teladoc High.
What was the news there?
Well, that's interesting.
So T Talk merged with Lavan Go, a diabetes management platform.
In 2020 they did a huge deal there.
And that's what we're trying to achieve now, because through AI and a little bit of research, we've found that using that platform and using, for example, personalized nudges, increases engagement and lowers C levels.
It is the diabetic insulin value that diabetics pay attention to.
So this is really what's contributing to the increased interest in Teladoc, you know, they've suffered from a decline in interest in telehealth due to the post-pandemic world.
This will really increase enrollment in chronic disease management.
Last year alone, half of Teladoc's enrollments were diabetes-focused, with the company reporting more than 1 million people enrolled in total on its chronic care platform.
This is really good news.
As a reminder, Teladoc is set to acquire Levon for $18.5 billion in 2020, but has posted a loss of $13.4 billion in 2022 as Levon's valuation has fallen.
So, this is still being built on that platform and they seem to still be sticking to it.
